Amara Apothecary

Dalron J. Robertson, is a Chicago-based research scientist and builder whose work spans biology, pharmacy, and intelligent systems. He is a Doctor of Pharmacy candidate at Chicago State University and an M.B.A. candidate at Mississippi College. He holds an M.S. in Biological Sciences from Mississippi College and a B.S. in Biology from Jackson State University, with additional training in software development at the University of Illinois Chicago. His practice treats bench work and code as one craft shaped by method, record, and result.

Robertson’s research centers on HPC-assisted discovery and bioinformatics. He has led protein structure and ligand–target studies using AlphaFold, CB-Dock2, and the Schrödinger suite, and he builds literature-aware knowledge models that keep scientists close to primary evidence. His projects emphasize clear data lineage, auditable pipelines, and visuals that make complex findings usable across teams.

He complements academic work with industry immersion through Astellas Pharma’s Bridge to Industry mentorship, gaining perspective on quality, research, and regulatory pathways. At Chicago State University College of Health Sciences & Pharmacy he serves as a Student Ambassador and sits on the Academic Curriculum Committee. He is a member of SNPhA and APhA–ASP, and he contributes to the College's Community Health Outreach Team. Prior roles in pharmacy informatics and long-term care operations sharpened his sense for workflow, safety, and reliable delivery.

His scholarship has been recognized at Mississippi College’s Research Symposium, where his Nigella sativa project earned second place for a computational and experimental pipeline that linked bioinformatic profiling to wet-lab validation. He has presented work on computational drug discovery, AI ethics in biotechnology leadership, and genomics.

Robertson is also a published author, which informs his approach to tone and clarity across disciplines. He favors plain language, measured claims, and records that hold up to scrutiny. His focus now is to advance AI pharmacology, strengthen clinical collaborations, and translate careful science into tools for everyday care.